August 1, 2025 | AI, Patient Retention, clinical trials, patient recruitment
Artificial intelligence (AI) in clinical research has the potential to accelerate patient access to new treatments by streamlining the drug development process and helping to generate more robust data, which will inevitably aid regulatory decision-making.

Eloise Moffatt, our Vice President of Commercial, joined other industry experts during a webinar about AI trends and technologies for 2025. They discussed the benefits that AI and machine learning (ML) can bring to clinical trials and the potential pitfalls that require careful consideration.
Read more here
This content was provided by Innovative Trials
Company Details
Latest Content from Innovative Trials
Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to…
We have seen a growing focus on patient diversity in clinical trials in recent years, but the COVID-19 vaccine trials in particular have highlighted the importance of achieving diverse patient…
UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis
Innovative Trials and Parexel invite you to attend the live webinar
The patient recruitment organisation has been shortlisted in the Inspiring Hertfordshire awards
Kate Shaw, Founder & CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation.
A key requirement for clinical trials is to understand the effect of potential treatments on the patient populations that will benefit most. Despite this, many studies find diverse patient recruitment…
Phase IIa Moderate to Severe Hidradenitis Suppurativa Case Study
In the latest blog post, Innovative Trials’ Equality & Diversity committee focuses on eating disorders
Innovative Trials, Pfizer and Parexel invite you to attend the live webinar
